بنام خداوند جان و خرد بنام خداوند جان و خرد.

Slides:



Advertisements
Similar presentations
Complications related to Treatment of Leukemia Fever and Neutropenia Aziza Shad, MD Lombardi Cancer Center Georgetown University Hospital Washington DC.
Advertisements

Yong Lee ICU Registrar John Hunter Hospital
Ventricular Assist Device Exit Site Care
1 Understanding the Blood Count in the Pediatric Oncology Patient Gina Brandl RN, BSN, MSN-Cand Pediatric Clinical Nursing Instructor Mid-State Technical.
PREVENTION OF CATHETER ASSOCIATED URINARY TRACT INFECTIONS (CAUTIs)
Introduction to Clinical Pharmacology Chapter 9 Antibacterial Drugs That Interfere With DNA/RNA Synthesis.
Antimicrobial Prophylaxis in Neutropenic Adult Oncology Outpatients ASCO Clinical Practice Guideline.
Febrile Neutropenia Chart Review and New Guideline Stephanie Eason RN, CPHON Kids Rock Conference October 2014.
Copyright Hancock 2013 Neutropenic Sepsis in Patients with Cancer Barry Hancock Emeritus Professor of Oncology University of Sheffield 11 th October 2013.
Chemotherapy Out of Hours Triage: Neutopenic Fever Jeanette Ribton Oncology CNS Project No: 26 08/09 Produced by: J Anders C-GARRD Presented: September.
+ Neutropenic sepsis Jackie Thomson. + OBJECTIVE AND OUTCOME Apporoach to a patient with neutropenic fever DEFINITION/ABBREVIATION NF = neutropenic fever.
SEPSIS KILLS program Adult Inpatients
Identify patient at risk for Candida infection Major risk factors includeOther risk factors include Previous bacterial infection and therapy Tunneled venous.
Febrile Neutropenia Allison Ferrara, MD Princeton Baptist Medical Center Baptist Health Systems Alabama.
Pam Charity, MD Cathryn Caton, MD, MS.  Define pneumonia  Review criteria for diagnosis  Review criteria for admission  Review treatment options.
Use of antibiotics. Antibiotic use Antimicrobials are the 2 nd most common drugs prescribed by office based physicians In USA1992: 110 million oral antimicrobial.
Management of Neutropenic Fevers in cancer patients Jerry Yu.
Edi Hartoyo Alan R. Tumbelaka Infectious Disease and Tropical Pediatrics Working Group Indonesian Pediatrician Society 1.
Management of Adverse Effects of Taxane Therapy: Focus on Neutropenia Brenda K. Shelton, MS, RN, CRN, AOCN Clinical Nurse Specialist The Sidney Kimmel.
Antimicrobial Stewardship Program JMH House staff Orientation 2012 Lilian Abbo, MD Assistant Professor Clinical Infectious Diseases Laura Smith, PharmD.
Plans for Diagnosis and Management of Acute Pyelonephritis.
Febrile Neutropenia Pedia Case. History AZ, 4 yo male from Bulacan admitted for the 3 rd time CC: fever for 3 days HPI: -Diagnosed w/ ALL since 3 yo -Has.
Case presentation Musab bin shuayl, MD.
Pharmacotherapy III Fall Major host factors that predispose patients to infectious disease 2. Management of neutropenic fever 3. Site-specific.
Treatment of urinary tract infections Prof. Hanan Habib.
NYU Medical Grand Rounds Clinical Vignette Lindsay Innes, MD PGY2 September 20, 2011 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
Neutropaenic Sepsis Based on the 2002 IDSA Guidelines for Use of Antimicrobial Agents in Neutropaenic Patients with Cancer.
Life-Threatening Infections: Diagnosis and Antimicrobial Therapy Selection.
Clare Dikken Macmillan Senior Chemotherapy Nurse Sussex Cancer Network
Overview of Agranulocytosis Stan Gerson, MD Chief, Division of Hematology & Oncology Asa & Patricia Shiverick Professor of Hematological Oncology University.
Initial Management of Fever or Suspected Infection In Paediatric Oncology and Stem Cell Transplantation Patients Clinical Practice Guideline 1 st edition.
VII. Treatment. Outpatient Triage n No hemorrhagic manifestations and patient is well-hydrated: home treatment n Hemorrhagic manifestations or hydration.
Treatment of urinary tract infections
Risk factors for severe disease from pandemic (H1N1) 2009 virus infection reported to date are considered similar to those risk factors identified for.
Evaluation of Peripheral blood
Infections in cancer patients Cancer patients are prone to infections because of: Cancer itself Disturbance of the immune system Anatomical obstruction.
Neutropenic Sepsis (NS)
Managing Candidemia JEANNE FORRESTER, PHARMD, BCPS PGY2 INFECTIOUS DISEASES PHARMACY RESIDENT MEDICAL UNIVERSITY OF SOUTH CAROLINA.
Infection Prevention in the Cancer Center Clinical Infectious Diseases 2013;57(4):579–85 R3 조영학 / Prof. 박기호.
BY lecturer / Hend Hamdey Rashed Clinical oncology & Nuclear medicine.
Empirical versus Preemptive Antifungal Therapy for High-Risk, Febrile, Neutropenic Patients: A Randomized, Controlled Trial Clinical Infectious Diseases.
MANAGEMENT OF NEUTROPENIC FEVERS IN CANCER PATIENTS Jerry Yu.
Antibiotics in Addition to Systemic Corticosteroids for Acute Exacerbations of Chronic Obstructive Pulmonary Disease Johannes M.A. Daniels; Dominic snijders;
Neutropenic sepsis Dr Christopher Dalley Consultant Haematologist.
Comparison between pathogen directed antibiotic treatment and empiri cal broad spectrum antibiotic treatment in patients with community acquired pneumonia.
Copyright © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins Introduction to Clinical Pharmacology Chapter 07- Penicillins.
Clinical Case Conference #5 Amaro - Aribon. Pathomechanisms for Cytopenia in Active SLE.
HAP and VAP Guidelines Update
Yadegarynia, D. MD..
بنام خدا.
Febrile Neutropenia in Paediatric Oncology – What do the rest do?
By: Wajidah Abdul-Khabir PGY-2
Fever in infants: Evaluation by
Management of Urinary Tract Infections Renal Block
Management of Urinary Tract Infections Renal Block
Using Risk-assessment tools to explore the scope
FEVER WITHOUT LOCALIZING SIGNS
Clinical Case Conference #5
Pathophysiology of Febrile Neutropenia
Use of antibiotics.
Shigellosis Bacterial dysentery.
Infections In The Immunocompromised Host
Hospital acquired infections
Sepsis: How Laboratory Can Help Mackenzie Roesti, RN, MSN, CCRN
Neutropenic sepsis case
Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department  Christopher.
Introduction to Clinical Pharmacology Chapter 9 Antibacterial Drugs That Interfere With DNA/RNA Synthesis.
Should I still screen for possible sepsis with SIRS criteria?
Endocarditis is an inflammation of the endocardium, the membrane lining the chambers of the heart and covering the cusps of the heart valves. Infective.
Presentation transcript:

بنام خداوند جان و خرد بنام خداوند جان و خرد

Strategies for the prevention of infection Avoid hospitalization if possible Avoid overcrowding and unnecessary through-traffic Enforce strict hand washing Segregate patients with communicable disease Consider protective isolation for high-risk patients Ensure proper construction and frequent upkeep of ventilation system Provide serial monitoring system for microbial contamination

Decreasing Microbial Colonization of the patients Provide prompt treatment or perior active site of infection Use immunosuppresive drug judiciously Avoid invasive unnecessary procedures Monitor serologies and clinical course in patients with unknown history of infection exposure (such as hepatitis B & tuberculosis) and consider prophylactic drug Consider prophylactic antimicrobials in high risk patients

Febrile Neutropenia is : an axillary temperature >38.5°C lasting >1 h in the context of an absolute neutrophil count (ANC) <0.5 × 109/l.

All neutropenic patients who meet eligibility criteria should be: * Immediately assessed for localizing signs or symptoms of infection * Immediately assessed for signs of sepsis and septic shock. * Treated empirically with antibiotics within one hour of fever or other eligibility criteria

Initial assessment and investigation . Initial assessment and investigation 1. Note presence of indwelling i.v. catheter 2. Symptoms or signs suggesting an infection focus     Respiratory system     Gastrointestinal tract     Skin     Perineal region/genitourinary discharges     Oropharynx     Central nervous system 3. Investigations     Routine blood testing to assess bone marrow, renal and liver function     Coagulation screen     C-reactive protein     Blood cultures (minimum two sets) including cultures from i.v. catheter     Urinalysis and culture     Sputum microscopy and culture     Stool microscopy and culture (if diarrhea present)     Skin lesions (aspirate/biopsy/swab)     Chest radiograph (if respiratory symptoms present or outpatient therapy considered)

MASCC scoring index Characteristic Score *Burden of illness: no or mild symptoms 5 *No hypotension *No chronic obstructive pulmonary disease 4 *Solid tumor or no previous fungal infection *No dehydration 3 *Burden of illness: moderate symptoms *Outpatient status (at onset of fever) *Age <20 years 2 Scores >21 are at low risk of complications.

When a patient with neutropenic fever also has Sepsis: When a patient with neutropenic fever also has abnormalities in vital signs, either heart rate>90 or respiratory rate>20, Severe Sepsis: When a patient with sepsis develops the new onset of any organ dysfunction

Empiric antibiotic regimens in febrile neutropenic Low risk: oral (ciprofloxacin+coamoxiclave) IV (monotherapy) (Vancomycin not needed) cefepime or ceftazidime or carbapenem High risk: vancomycin not needed :1-monotherapy 2-Two drugs: Aminoglycosids+(Antipseudomonal penicillin or cefepime or ceftazidime or carbapenem) vancomycin needed: vancomycin+ cefepime or ceftazidime or carbapenem +_ Aminoglycosids

daily follow-up and assessment of response Daily assessment of fever trends, bone marrow and renal function is indicated until the patient is apyrexial and ANC ≥ 0.5 × 109/l If apyrexial and ANC ≥ 0.5 × 109/l at 48 h Low-risk and no cause found: consider changing to oral antibacterials. High-risk and no cause found: if on dual therapy, aminoglycoside may be discontinued. When cause found: continue on appropriate specific therapy.

:If still pyrexial at 48 h If clinically stable: continue initial antibacterial therapy. If clinically unstable: antibacterial therapy should be rotated or cover broadened if there are significant clinical reasons to do that. This group of patients is at risk of serious complications and prompt advice from an ID physician or clinical microbiologist should be sought. When the pyrexia lasts for >4–6 days, initiation of antifungal therapy may be needed.

duration of therapy: If the neutrophil count is ≥0.5 × 109/l, the patient is asymptomatic and has been afebrile for 48 h and blood cultures are negative, antibacterials can be discontinued. If the neutrophil count is <0.5 × 109/l, the patient has suffered no complications and has been afebrile for 5–7 days, antibacterials can be discontinued except: in certain high-risk cases with acute leukemia and following high-dose chemotherapy when antibacterials are often continued for up to 10 days, or until the neutrophil count is ≥0.5 × 109/l. Patients with persistent fever despite neutrophil recovery should be assessed by an ID physician or clinical microbiologist and antifungal therapy considered.